cs0159

Primary Biliary Cholangitis

Cascade Pharmaceuticals, IncPhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 89/ 100

Competitive context

18 Active assets in the Primary Biliary Cholangitis cohort.

Asset / Sponsor	Phase	Rating
URSODEOXYCHOLIC ACID Xijing Hospital of Digestive Diseases	Phase 4	A
Saroglitazar Zydus Therapeutics Inc.	Phase 3	BB
Fenofibrate Xijing Hospital of Digestive Diseases	Phase 3	BB
Obeticholic Acid Intercept Pharmaceuticals	Phase 3	BB
Mbx-8025 Gilead Sciences	Phase 3	BB

View all 50 →

Same molecule, other indications

cs0159 is also rated in:

primary sclerosing cholangitisDormant

B

Indicative ·

58 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

57 / 100

type 2 diabetes mellitusDormant

D

Indicative ·

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.